top of page

Lymphoma Research Groningen(LRG)

Latest news

January 2021: Kickoff meeting of the H2020-TWINNING project "ON THE ROAD TO EXCELLENCE IN UNRAVELLING THE (EPI)GENETIC LANDSCAPE OF HEMATOLOGIC NEOPLASMS" (, a consortium between the Institute of Human Genetics (Poznań, Maciej Giefing), UGhent (Pieter van de Vlierberge), UULM (Reiner Siebert) and the LRG of the UMCG (Anke van den Berg, Lydia Visser en Joost Kluiver) 

October 2020: Dr. Fubiao Niu received his PhD after defending his thesis “The roles of noncoding RNAs in B-cell lymphomas”. Dr. Niu who worked in a team guided by Dr. Joost Kluiver and Prof. Anke van den Berg, will continue his scientific career as a postdoc in Bejing, China.

September 2020: Hematologist Dr. Tom van Meerten receives 30 million to set up a CAR T-cell facility in the UMCG. The project is in close collaboration with the Radboud MC, Erasmus MC and the Amsterdam UMC. In Groningen, Rotterdam and Amsterdam patients will be treated with CAR T-cells generated in Groningen. For further reading see here and here (in Dutch).

LRG background information

In the University Medical Center Groningen research in the field of lymphoma is mainly clustered in the LRG. Members of the LRG are a mix of clinicians and basic scientists of five departments. These include Hematology, Medical Imaging Center, Pathology, Radiotherapy as well as the Trial data center.

The lymphoma research is embedded within the ‘Stem cells, Ageing, Leukemia and Lymphoma’ (SALL) program. This program is one of the four main research programs of the Cancer Research Center Groningen (CRCG). Moreover, the work of the LRG is embedded in the graduate school of medical sciences (GSMS).

Research lines of the LRG focus on the most common B-cell lymphoma types. The main aim is to deepen the insights into biologic mechanisms and translate these to the clinic. Results from these biology-driven studies are then translated into clinical studies. These studies include testing the value of diagnostic markers for lymphoma classification, implementation of biomarkers for prediction of treatment response and designing better treatment schedules. Altogether, we aim to improve outcome of lymphoma patients by implementing novel biomarkers and treatment schedules.

The UMCG is the reference center for other hospitals in North Netherlands. In total, we cover a region with 3,5 million inhabitants.

For patient information please visit:

For more information about CRCG please visit:

bottom of page